Castle Biosciences Inc. Discloses Lobbying and Insider Trading Trends
$40,000 of CASTLE BIOSCIENCES INC. lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing.
This included lobbying on issues such as:
“Issues relating to Medicare coverage for laboratory diagnostic services.”
For more information on corporate lobbying, visit Quiver Quantitative.
Recent Trends in CSTL Insider Trading
Insiders at CSTL have engaged in 163 trades of $CSTL stock over the past six months, exclusively selling shares with no purchases recorded. Here’s a breakdown of the recent trading activity:
- DEREK J MAETZOLD (President & Chief Executive Officer) traded 129 times, selling 80,793 shares.
- DANIEL BRADBURY traded 24 times, with 39,351 shares sold.
- FRANK STOKES (Chief Financial Officer) traded 4 times, selling 16,923 shares.
- TOBIN W JUVENAL (Chief Commercial Officer) traded 2 times and sold 6,607 shares.
- KRISTEN M OELSCHLAGER (Chief Operating Officer) traded 4 times, with 18,821 shares sold.
For more on insider transactions, check out Quiver Quantitative’s insider trading dashboard.
CSTL Hedge Fund Movements
In the latest quarter, 112 institutional investors increased their holdings in CSTL stock, while 62 reduced their positions.
Some significant changes include:
- DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) removed 857,666 shares (-98.1%) in Q3 2024.
- GRANAHAN INVESTMENT MANAGEMENT, LLC reduced holdings by 633,721 shares (-59.8%) in Q3 2024.
- WASATCH ADVISORS LP cut their position by 501,844 shares (-21.6%) in Q3 2024.
- POINT72 ASSET MANAGEMENT, L.P. added 445,415 shares (+828.3%) to their portfolio in Q3 2024.
- NUVEEN ASSET MANAGEMENT, LLC increased their holdings by 256,082 shares (+89.4%) in Q3 2024.
- DEUTSCHE BANK AG removed 249,339 shares (-80.6%) in Q3 2024.
- SILVERCREST ASSET MANAGEMENT GROUP LLC added 201,921 shares (+inf%) in Q3 2024.
For insights on hedge fund portfolios, visit Quiver Quantitative’s institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative’s disclaimers for additional information.
This article was originally published on Quiver News; read the full story.
The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.
